336 results about "Sepsis" patented technology

The invention specifically relates to a clinical deterioration risk prediction and early warning system and method based on machine learning, and relates to the technical field of medical artificial intelligence and clinical informatics, and the method comprises the steps: obtaining multi-dimensional time series data in real time; constructing a dynamic feature engineering vector; machine learning risk prediction; judging a risk threshold value and triggering early warning; and interpretation and suggestion generation driven by the large language model. According to the method, multi-dimensional time sequence data is continuously acquired in real time, multi-sliding window statistical features and standardized clinical deterioration scores are extracted in combination with dynamic feature engineering, and accurate quantitative risk prediction of multiple disease deterioration types such as sepsis and respiratory failure is realized by means of machine learning models which are specifically trained by XGBoost, LSTM and the like. The problem that traditional early warning depends on manual judgment and is high in hysteresis is effectively solved; medical staff can be helped to quickly grasp the core inducement of disease deterioration, and a standardized and landing action scheme is provided.

The invention discloses a macrophage-targeting inhalable nano material, a preparation method thereof and application of the inhalable nano material in treatment of sepsis myocarditis, and belongs to the technical field of medicines. The nano-material is a nano-liposome, the nano-liposome comprises a mannose modified nano-liposome microsphere, and the mannose modified nano-liposome microsphere comprises a liposome skeleton shell layer, a drug and a targeting layer; the liposome skeleton shell layer comprises soybean lecithin and cholesterol; the medicine comprises quercetin and TPPU (Thermoplastic Polyurethane); and the targeting layer is formed by connecting mannose modified DSPE-PEG2000 to the outer surface of the liposome skeleton shell layer. The nano material can accurately target macrophages at a cardiac inflammation part, has a multi-target-point synergistic effect, is more convenient and faster in administration, remarkably improves the safety and comprehensively improves the treatment effect.

The invention belongs to the field of biological medicines, and relates to a drug-loaded nano-vesicle as well as a preparation method and application thereof. The drug-loaded nano-vesicle comprises a vesicle core and a drug-loaded nano-vesicle, wherein the vesicle core comprises siRNA (small interfering Ribonucleic Acid) capable of specifically targeting and silencing an NR1D1 gene; the vesicle membrane is formed by fusing an erythrocyte membrane, a macrophage membrane, cardiolipin, cholesterol and lecithin. The drug-loaded nano-vesicle can specifically target macrophages in a sepsis immunosuppression stage, has an intracellular response release function, recovers BMAL1 and IGF2BP2-ATP6V1B2 / ATP6V0c axis functions by inhibiting NR1D1 expression, reconstructs a macrophage phagocytosis function and lysosome-dependent bacterium removal capability, and can be used for preparing a drug-loaded nano-vesicle with a specific targeting function. The survival rate of sepsis immunosuppression model animals is obviously improved; and the bacterial load is reduced. Compared with a traditional electroporation method, the preparation method disclosed by the invention has the advantage that the encapsulation efficiency of siRNA is remarkably improved.

The invention relates to the technical field of medical data mining, and particularly discloses an elderly sepsis index model, a prediction model construction method and a prediction system.The method comprises the steps that a development queue data set and an independent verification queue data set of elderly sepsis patients at the age larger than or equal to 60 years old are determined according to an intensive care database; performing sepsis death and prognosis importance sorting on candidate inflammation-immune composite indexes of the development queue data set according to a total correlation feature selection algorithm; superposing and combining preset basic indexes, each index in the importance inflammation marker indexes and a preset importance scoring standard; comparing the scoring results of the multiple groups of joint optimization index models, and evaluating the scoring results; and determining the joint optimization index model with the optimal evaluation result as the senile sepsis index model. According to the construction method of the senile sepsis index model provided by the invention, the index model suitable for senile sepsis can be obtained based on the existing index database.

The invention discloses a medicine composition for inducing fibroblasts to be reprogrammed into pericyte-like cells (PCLCs) through a chemical small molecule combination, and the medicine composition is used for treating sepsis. According to the invention, a chemical reprogramming strategy without genetic modification is adopted, an endogenous signal channel is activated through a time sequence, and fibroblasts from somatic cells are efficiently converted into PCLCs with high expression of genes such as EMILIN3, LAMC3, GDF10, AHR, CD109, AHR, NQO1, QPRT and the like. When applied to treatment of sepsis, the medicine composition can improve pathological symptoms and reduce death rate by synergistically exerting anti-inflammatory, anti-oxidation, immune regulation and tissue barrier protection effects. The invention provides a novel safe treatment strategy based on non-genetically modified cells for sepsis.

The invention provides a sepsis multi-task prediction method and system, and belongs to the technical field of disease prediction based on a mathematical model, and the method comprises the steps: obtaining a symptom data record of a to-be-detected patient; and processing the obtained symptom data records by using a pre-trained classification model to obtain a final task result. According to the method, a multivariable time sequence in medical health record data of a patient is utilized, time representation containing sepsis pathological characteristics is obtained through a time mode of modeling data based on a self-attention encoder, and the trend of the condition of the patient changing along with time is obtained; correlating different medical features according to features including patient condition change trends, so that each feature can perceive other features mutually, and mining global feature representation of the patient; and inputting the global feature representation into a task-aware hybrid expert system, and routing the unified global feature representation into different expert systems, thereby obtaining task-level representation and realizing multi-task prediction.

The invention discloses a sepsis multi-complication prediction method and system, a storage medium and equipment, and belongs to the technical field of intelligent medical treatment, and the method comprises the following steps: S1, collecting multi-dimensional time sequence physiological data of a sepsis patient; s2, constructing a medical perception feature vector for the time sequence physiological data; s3, constructing a sepsis multi-complication prediction model and introducing a physiological logic space-time composite mask matrix; s4, outputting a multi-complication prediction probability by adopting a hierarchical expert hybrid network H-MoE; s5, training the model by adopting a dynamic weighting loss function based on task uncertainty; s6, risk output and feature contribution degree explanation; according to the model, by introducing physiological logic masks and an H-MoE framework, precise and synchronous prediction of complex complications of sepsis is achieved, redundant features can be effectively filtered, complex association between the redundant features can be revealed, quantitative decision support is provided for clinicians, and therefore early intervention and personalized treatment are achieved.

The embodiment of the invention provides a sepsis prediction method, electronic equipment and a medium, and the method comprises the steps: inputting expression data corresponding to a plurality of different target genes of a patient into a sepsis prediction model, and obtaining a sepsis prediction result of the patient; wherein the sepsis prediction model is obtained through the following steps that a plurality of first training samples are obtained, and the first training samples comprise sample expression data of all target genes; for each first training sample, inputting the first training sample into a pre-trained analytical model to obtain a training prediction result of the first training sample and contribution relationship information between each piece of sample expression data in the first training sample and the training prediction result; and adjusting the initial sepsis prediction model according to the multiple pieces of contribution relationship information corresponding to the first training samples to obtain the sepsis prediction model. According to the embodiment of the invention, the accuracy and reliability of sepsis prediction can be improved.

The invention discloses an application of a PLSCR1 protein in preparation of a biomarker for evaluating early warning of sepsis. The invention determines and verifies that the PLSCR1 is obviously increased in sepsis patients for the first time. According to the invention, the PLSCR1 is used as a novel biomarker for early warning and prognosis evaluation of sepsis, so that the clinical early recognition and prognosis capability is effectively improved. The PLSCR1 shows an independent prediction value, detection of the PLSCR1 level of a suspected or diagnosed sepsis patient can provide a more accurate and more comprehensive basis for clinical decision making, and improvement of the survival outcome of the patient and optimization of the treatment effect are facilitated.

The invention relates to the technical field of biological medicines, and particularly discloses application of betaine in preparation of a medicine for preventing or treating sepsis myocardial injury. Betaine (BET) provided by the invention can be used for effectively relieving cytokine storm caused by sepsis injury and inhibiting reduction of core body temperature of a mouse; the abnormal blood routine and blood biochemical indexes are improved. In addition, betaine can reduce generation of active oxygen in myocardial cells of the HL-1 mouse and improve mitochondrial membrane potential imbalance of the myocardial cells of the HL-1 mouse. The chemical structural formula of the betaine is shown in the specification.

The invention provides application of 4-CMTB or pharmaceutically acceptable salt thereof in preparation of a medicine for treating sepsis. The invention further provides application of the 4-CMTB or the pharmaceutically acceptable salt of the 4-CMTB in preparation of drugs for promoting expression of HO-1, xCT, GPX4, IL10 and ARG1. The invention also provides an application of the 4-CMTB or the pharmaceutically acceptable salt thereof in preparation of drugs for inhibiting the expression of TNF-alpha and / or reducing the levels of ROS and LOOH. Experimental results show that 4-CMTB is expected to become a medicine for treating sepsis.

The invention belongs to the technical field of gene engineering and protein engineering, and particularly relates to a fully human antagonistic antibody taking a lactylated STAT6 protein as a target spot and application of the fully human antagonistic antibody. According to the present invention, the completely humanized antagonistic antibody using the lactylated STAT6 protein as the target spot is screened from the human scFv phage antibody library, the amino acid sequence of the completely humanized antagonistic antibody is represented by SEQ ID NO: 1, and the completely humanized antagonistic antibody has the specificity of the targeted lactylated STAT6 protein, and has the application prospect in preparation of the product for diagnosis, treatment or alleviation of sepsis immunosuppression.

The present invention provides novel drug-linker conjugates and antibody-drug conjugates of imidazo quinoline amine derivatives, which have agonistic activity against Toll-like receptors (TLRs), in particular TLR7 and / or TLR8, also provided are pharmaceutical compositions and methods of treatment against certain diseases or conditions mediated by or associated with TLR7 and / or TLR8 (e.g., graft rejection, autoimmunity, inflammation, allergy, asthma, infection, sepsis, cancer, and immunodeficiency).

The application discloses application of a pyrimidinotriazine diketone derivative in preparation of a medicine for inhibiting activity of human protease caspase-1, and belongs to the technical field of medicines. In view of defects of existing caspase-1 inhibitors, the compound has the characteristics of high affinity binding to caspase-1 (K D = 8.11 μM; 8.78 μM) and strong inhibition on the activity (IC 50 = 11.90 nM-14.47 nM). The compound is used for preparation of a medicine for inhibiting the activity of caspase-1 and a medicine for treating inflammation-related diseases such as sepsis-related lung injury, acute respiratory distress syndrome or acute pancreatitis.

The invention belongs to the technical field of pharmacy, and particularly relates to application of urolithin A in treating multiple organ injuries caused by sepsis. Experiments prove that the urolithin A can significantly reduce the apoptosis rate of bone marrow-derived macrophages, and can effectively relieve multi-organ injury caused by sepsis by regulating three key paths including oxidative stress, cell apoptosis and necrotic apoptosis. The application provides solid experimental basis and theoretical support for development of urolithin A as a sepsis treatment drug, and has important conversion value and clinical application prospect in the critical disease medical field.

To provide a type C natriuretic peptide and a method for treating acute lung injury. [Solution] This disclosure relates to the treatment of lung, liver, and / or kidney disorders by administering therapeutically effective doses of (ultra)long-acting C-type natriuretic peptide (CNP), CNP derivatives, (ultra)long-acting CNP derivatives, or (ultra)long-acting CNP receptor (NPRB) agonists to subjects in need. This disclosure also relates to the treatment of non-cardiovascular causes of hypoxia, elevated inflammatory cell levels in the lungs, pulmonary edema, sepsis, bacteremia, fibrosis in general, and / or interstitial lung disease using these.

The invention discloses a blood perfusion adsorbent for adsorbing endotoxin by double acting forces as well as a preparation method and application of the blood perfusion adsorbent. The adsorbent (PS-DVB (at) p (CD-His)) is subjected to raft polymerization through 4-cyano-4-(thiobenzoic acid) valeric acid grafted on the surface of PS-DVB to generate a glycidyl methacrylate brush polymer, and is combined with an L-histidine modified cyclodextrin functional molecule; the positive charges of histidine groups and the hydrophobic cavities of the cyclodextrin are used for realizing electrostatic and hydrophobic interaction to synergistically and efficiently adsorb endotoxin. The materials of the blood perfusion adsorbent are easy to obtain, the cost is low, the blood perfusion adsorbent has good blood compatibility and endotoxin adsorption performance, the development of the adsorbent is beneficial to in-vitro blood perfusion treatment of septicopyemia patients, and the clinical treatment cost is reduced.

The invention provides a medicine for treating sepsis-related acute kidney injury, belongs to the technical field of small molecule medicines, and particularly provides a medicine for treating sepsis-related acute kidney injury, which comprises a NOX4 inhibitor. And the NOX4 inhibitor comprises GLX351322 (GLX351322). According to the application, it is clear that the NOX4 level in serum of an S-AKI patient is remarkably increased and is in positive correlation with kidney injury, it is proved that GLX351322 has remarkable treatment and renal function protection effects on acute kidney injury caused by bacterial infection or acute kidney injury caused by lipopolysaccharide exposure, and a new treatment target and a new drug development direction are provided for sepsis-related acute kidney injury.

The invention relates to the technical field of sepsis monitoring, and discloses a sepsis monitoring method and system based on multi-modal data, and the method comprises the steps: setting a plurality of sepsis patient types based on influence factors, and generating a plurality of disease course period sequences which comprise a plurality of disease course periods, each disease course period is mapped with a corresponding multi-modal data set; comparing and analyzing the multi-modal data sets of the plurality of disease course cycle sequences to obtain feature data of each disease course cycle, change features of each feature data and a weight coefficient, and constructing a sepsis monitoring model; the real-time characteristic data of the to-be-monitored patient is obtained and input into the sepsis monitoring model, the monitoring result is obtained, whether the early warning instruction is generated or not is judged, the complexity of sepsis and the individual difference of the patient are fully considered, the monitoring accuracy is improved, and powerful support is provided for timely diagnosis and treatment of the sepsis patient.

The invention discloses a traditional Chinese medicine composition for treating sepsis as well as a preparation method and application of the traditional Chinese medicine composition. The traditional Chinese medicine composition is prepared from 1-15 parts of sulfur, 3-25 parts of calamitas urinae hominis, 1-20 parts of wine-treated rhubarb, 10-30 parts of fructus cannabis, 10-50 parts of radix bupleuri, 5-30 parts of scutellaria baicalensis, 5-25 parts of folium isatidis, 5-25 parts of peach kernels, 5-30 parts of salvia miltiorrhiza, 5-30 parts of angelica sinensis, 5-30 parts of sophora flower charcoal, 5-25 parts of fructus gardeniae praeparatus and 5-60 parts of wine-treated fructus corni. According to the invention, through a combined mode of'monarch drug targeted oral administration and synergistic decoction of minister, assistant and guide drugs', the whole-course intervention of'upstream inhibition, midstream blocking and downstream regulation 'on sepsis immune disorder can be realized, meanwhile, the functions of warming yang, dispelling cold, cooling blood and detoxifying are taken into account, and the pro-inflammatory / anti-inflammatory balance is successfully recovered to a physiological state; the action mode is superior to that of a traditional single anti-inflammatory strategy and a traditional Chinese medicine application mode of whole-prescription decoction. In a standard animal model, the traditional Chinese medicine composition definitely shows the dose-dependent extremely remarkable effects of anti-inflammation, immunoregulation, multi-organ protection and overall condition improvement, the curative effect of a high-dose group of the traditional Chinese medicine composition is equivalent to that of a classic potent medicine, and the traditional Chinese medicine composition has more advantages in the aspects of recovering immune homeostasis, warming yang and strengthening the body resistance.

The invention relates to the technical field of sepsis, in particular to a medicine regulation and control method and system for sepsis patients. Comprises: constructing a drug simulation model based on a historical diagnosis and treatment library; acquiring a feature feedback packet of the user to be treated, and setting a primary regulation strategy according to the feature feedback packet and the drug regulation model; acquiring a monitoring data packet according to a preset feedback time node, and judging whether to correct the first-level regulation and control strategy or not according to the monitoring data packet; rapid drug intervention for a user to be treated is achieved by setting drug sub-strategies of various disease types, meanwhile, a digital twinborn model for the user to be treated is constructed by collecting a real-time feedback data packet of the user to be treated and carrying out optimization fitting on an initial simulation sub-model, refined and real-time regulation and control of drug dosage are achieved, and the treatment effect of the user to be treated is improved. Therefore, the treatment efficiency is improved.

The invention relates to the technical field of medical auxiliary instruments, in particular to an auxiliary sepsis treatment device which comprises an outer tube, an occlusion seat sleeve is arranged on the outer side of the middle of the outer tube, an inner tube and a sleeve are arranged on the inner side of the outer tube, the sleeve is arranged between the inner tube and the outer tube and slidably connected into the outer tube, and the head of the sleeve is rotatably connected with a lantern ring and an opening part. The multiple distraction pieces are arranged on the lantern ring in an annular array mode, the distraction pieces wrap the outer side of the head of the inner pipe, and the problems that in the prior art, due to the fact that a device for auxiliary treatment of sepsis does not have a special fixing structure designed for a pipeline, the pipeline is prone to displacement and is indirectly pressed, the ventilation effect is affected, and the pipeline cannot be directly pressed are solved. And when the patient unconsciously occludes, no active early warning and resetting functions exist, the unconscious occlusion behavior of the patient cannot be monitored, resetting cannot be achieved through active actions of the patient, manual intervention of medical staff is needed, the nursing workload is increased, and discomfort is brought to the patient.

The present disclosure is drawn to an endolysin protein against Streptococcus pneumoniae (Spn), designated SP-CHAP. The disclosure provides methods of treating diseases in a subject resulting from infection with pneumococcal bacteria, said diseases including but not limited to pneumonia, invasive pneumococcal disease, meningitis and sepsis. Such treatment methods include administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising SP-CHAP polypeptide, polypeptide fragments, SP-CHAP encoding nucleic acids (RNA / DNA) or variants thereof.

The invention discloses a miR-424 and cerium oxide loaded plant external vesicle complex as well as a preparation method and application thereof, and belongs to the technical field of biological medicines and nano materials. The complex comprises plant external vesicles extracted from radix puerariae and a compound of miR-424 and cerium oxide nanoparticles loaded in the plant external vesicles. The preparation method mainly comprises the following steps: extracting plant extracellular vesicles from radix puerariae; the preparation method comprises the following steps: compounding cerium oxide nanoparticles and miR-424 according to a mass ratio; and co-incubating the obtained compound and plant outer vesicles to realize loading. The complex provided by the invention integrates the good biocompatibility of the plant exovesicles, the gene regulation function of the miR-424 and the antioxidant activity of the cerium oxide nanoparticles, is low in cytotoxicity under low concentration, and shows a better uptake tendency to macrophages. The complex can be used for preparing medicines, and particularly has application potential in prevention or treatment of inflammation or oxidative stress related diseases (such as sepsis and acute lung injury).

The invention relates to the field of medical treatment, and discloses a sepsis risk prompt detection method based on model prediction, which comprises the following steps of: collecting a clinical blood sample of an acute infection patient, matching gene expression characteristics of the clinical blood sample with a database through gene target analysis, primarily screening out gene expression data obviously related to sepsis, and comparing the gene expression data with the database; according to the gene expression data of the marked sepsis patient samples and the gene expression data of the non-sepsis patient samples, gene expression differences are obtained, differential gene data and clinical data are established, a machine learning algorithm model is trained, and a sepsis recognition model is obtained; differential gene detection data related to sepsis is input into a sepsis recognition model for prediction, a sepsis recognition result is output, the sepsis recognition result and detection data of a sepsis rehabilitation patient are compared and analyzed, a model prediction effect is evaluated, and early warning is performed on prediction and evaluation results. The accuracy of model prediction is improved, and the prediction capability of the model is enhanced.

The present invention relates to the field of liver disease, and more particularly to a method for determining the presence of chronic plus acute liver failure or for determining the risk of developing ACLF in a patient suffering from cirrhosis or a delayed early stage of ACLF. The invention also relates to a method for distinguishing patients suffering from decompensated liver cirrhosis, acute decompensated liver cirrhosis (ADC) or delayed ACLF from patients suffering from early ACLF or ACLF 1, 2, 3, a method for determining the degree of systemic inflammation and a method for determining the presence of a bacterial infection with sepsis.

Liposomal trans-crocetin pharmaceutical compositions, dosing regimens and methods of treating or preventing disorders and conditions associated with, but not limited to, infection, ischemia, hypoxia, ARDS, inflammation, sepsis, shock, stroke, traumatic injury, and proliferative disorders such as cancer are provided. Methods of using the provided trans-crocetin pharmaceutical compositions and dosing regimens to treat cardiovascular, renal, liver, inflammatory, metabolic, pulmonary, neurological, and other disorders and conditions are also provided, as are methods of increasing the delivery of oxygen and increasing the efficacy of a therapeutic agent using the provided compositions and dosing regimens.

The present invention relates to the use of antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, for restoring and / or normalizing epithelial barrier function for treating and / or preventing acute respiratory failure.In particular, antisecretory factor (AF) protein, homologues, and / or fragments thereof, having equivalent functional activity, and / or a pharmaceutically active salt thereof, is (are) herein disclosed to be of use in counteracting and / or normalizing fluid transfer across epithelial cell barriers with a significant impact on a large proportion of patients with traumatic lung injury, such as but not limited to patients suffering from abnormal accumulation of fluid in the lung alveoli and / or bronchioles selected from the list of patients suffering from BPD, ARDS, IRDS, sepsis, SIRS, acute pulmonary edema, pneumonia, interstitial pulmonary edema and cardiovascular lung disorder.

A subject can be treated for cardiogenic shock and / or sepsis, or their symptoms using platelet-derived extracellular vesicles (PEVs) or mitlets that include PEVS. The PEVs include mitochondria. The PEVs can be collected by obtaining blood from one or more donors, adding an anticoagulant and a buffer to the blood to form a mix, separating the mix into supernatant and platelet rich plasma (PRP), collecting the PRP and stimulating the collected PRP, thereby expelling extracellular vesicles from platelets in the PRP, and collecting the extracellular vesicles as the PEVs. PEVs can also be isolated from source cells grown in a bioreactor and suspended in a buffer to preserve the PEVs.